Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharmacol Res. 2014 Oct;88:74-83. doi: 10.1016/j.phrs.2014.06.007. Epub 2014 Jun 19.

Statins in neurological disorders: an overview and update.

Author information

1
Department of Medicine and Surgery, University of Salerno, Italy; Department of Pharmaceutical Sciences, University of Salerno, Italy. Electronic address: amalfitano@unisa.it.
2
Neurologia-Stroke Unit, Azienda Ospedaliera dei Colli Napoli, Italy; Brain and Vision Research Laboratory Boston University, Boston, MA, USA.
3
Department of Pharmaceutical Sciences, University of Salerno, Italy.
4
Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), Napoli 80131, Italy.
5
Department of Medicine and Surgery, University of Salerno, Italy. Electronic address: mbifulco@unisa.it.

Abstract

Statins have, at present, the potential to provide a new therapeutic target for various neurological diseases. It is well established that statins reduce cholesterol levels and prevent coronary heart disease. Moreover, evidence suggest that statins have additional properties such as endothelial protection via action on the nitric oxide synthase system as well as antioxidant, anti-inflammatory and anti-platelet effects. These properties might have potential therapeutic implication not only in stroke but also in neurological disorders such as Alzheimer disease, Parkinson's disease, multiple sclerosis and primary brain tumors. In addition to their potent anti-atherosclerotic and cardio-protective effects, compelling clinical and preclinical studies delineate the neuro-protective efficacy of statins in all these neurological disorders. It is apparent from these studies that most patients with central nervous system disorders probably benefit to some extent from lipid-lowering therapy. But data are not univocal, and we must also consider the adverse effects due to the administration of lipid-lowering therapy. Thus, in these scenarios the effectiveness of statins in treating stroke, Alzheimer's disease, Parkinson disease, multiple sclerosis, and primary brain tumors have to be conclusively proven in vivo and/or in adequate clinical trials.

KEYWORDS:

Alzheimer disease; Multiple sclerosis; Neuro-protection; Parkinson's disease; Primary brain tumors; Statins; Stroke

PMID:
24954580
DOI:
10.1016/j.phrs.2014.06.007
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center